Working at the Thailand Ministry of Public Health (MOPH) in Nonthaburi, the U.S. Centers for Disease Control and Prevention (CDC) collaborates with government and non-governmental partners in Thailand, including civil society organizations and multilateral organizations, to discover, evaluate and implement new tools, programs and policies to combat HIV, sexually transmitted infections (STIs), and tuberculosis (TB). It supports the Joint United Nations Programme on HIV/AIDS (UNAIDS) 90-90-90 goals (by 2020, 90 percent of all people living with HIV know their HIV status; 90 percent of all people with a diagnosed HIV infection receive antiretroviral treatment [ART]; and 90 percent of all people receiving ART are virally suppressed).

CDC Thailand works through two cooperative agreements - one with the Ministry of Public Health (MOPH) and a second with the Bangkok Metropolitan Administration (BMA) - to scale-up and evaluate effective approaches to reach and test men who have sex with men (MSM) and transgender women (TGW), and treat and retain people living with HIV (PLHIV) in Bangkok and four high HIV burden provinces. To accelerate HIV epidemic control in Thailand in Fiscal Year (FY) 2020, CDC Thailand aims to:

• Initiate testing for recent HIV infection and index partner testing to promote timely diagnosis and linkage to treatment and care through facility-based voluntary counseling and testing programs.

• Develop innovative models for and increase access to HIV self-testing.

• Promote use of pre-exposure prophylaxis (PrEP) to prevent new HIV-infections in the highest risk populations through targeted campaigns and by strengthening public PrEP services.

• Promotesame-day ART for HIV-positive people to ensure treatment initiation and prevent further transmission.

• Promote multi-month dispensing of ART for stable patients.

• Scale-up enhanced adherence counseling, the viral load testing network, and case manager programs to ensure 100 percent viral load testing access and 95 percent viral suppression and retain PLHIV in care.

• Expand data-driven quality improvement programs to enhance the quality of HIV services.

• Advocate for rapid transition to once-a-day, fixed-dose combination antiretroviral that consists of tenofovir disoproxil fumarate, lamivudine, and dolutegravir (TLD).

Thailand.pdf